Aide Health is a technology company.
Aide Health has raised $1.0M across 1 funding round.
Aide Health has raised $1.0M in total across 1 funding round.
Aide Health has raised $1.0M in total across 1 funding round.
Aide Health's investors include American Express Ventures, B Capital Group, Blockchain Capital, Cedar Capital Group, Chemistry VC, Citi Ventures, Coinbase Ventures, Hambro Perks, Rajan Anandan, Tapas Capital, Pierre Lavaux, Scott Belsky.
Aide Health is a design-led health technology company founded in 2021 and based in London, UK, that builds a conversational AI-powered digital platform to empower patients and clinicians in managing chronic diseases.[1][2][3] The platform addresses key challenges like low health literacy (affecting 4 in 10 adults), poor medicine adherence (50% non-compliance leading to half of treatment failures), and the burden of self-management outside clinics (over 80% of chronic care).[3][4] It serves patients with long-term conditions such as asthma, type 2 diabetes, hypertension, and COPD—primarily through healthcare systems like the NHS—and supports clinicians with insights for better consultations, while aiding life sciences in patient engagement and real-world evidence (RWE).[1][2][4][5] Aide demonstrates strong growth momentum with a 30-day patient retention rate of 1 (implied high, ~18x digital health app average), average medicine adherence boosted from 35-50%, and users managing multiple medicines at an average age of 52.[3]
Aide Health emerged in 2021 amid rising demand for digital tools to handle comorbidity—the increasing prevalence of patients with multiple chronic conditions, now affecting one in three emergency hospital admissions (up from one in ten a decade ago) and 50% of GP appointments.[2][4] While specific founders are not detailed in available sources, the company was established in London with a design-led approach, starting with support for asthma and type 2 diabetes before expanding to hypertension, COPD, and plans for chronic kidney disease (CKD) and heart failure by late in the demo year referenced.[1][5] Early traction built on evidence that patient self-management reduces hospitalizations and improves sustainability, with the platform launching as the first medical AI note-taker for patients and caregivers, focusing on conversational AI for daily engagement.[1][3][5]
Aide Health rides the wave of AI-driven digital health transformation, targeting the explosion in chronic disease comorbidity reshaping systems like the NHS, where 20% of 25-64-year-olds have multiple conditions and chronic care dominates appointments.[4] Timing is ideal amid post-pandemic remote monitoring needs and AI advancements in structured conversations, enabling scalable self-management that cuts hospital admissions and supports evidence-based care—aligning with global pushes for sustainable healthcare.[1][3] Market forces like aging populations (two billion adults with chronic diseases), low adherence inefficiencies, and demand for real-world evidence favor Aide, positioning it against competitors like Lenus Health (predictive AI for COPD/heart failure), Huma (remote monitoring/virtual wards), and Healthmine (engagement analytics).[2] It influences the ecosystem by bridging patient-clinician gaps, enhancing health literacy, and providing broad data platforms for research, potentially accelerating AI adoption in public health systems.[1][3][5]
Aide Health is poised for expansion with upcoming CKD and heart failure support, leveraging its high retention and adherence metrics to penetrate more health systems and life sciences partnerships amid AI-health convergence.[3][5] Trends like multimodal AI (audio/text integration) and comorbidity-focused platforms will shape its path, amplifying impact as data from diverse users fuels advanced insights and RWE. Its influence may evolve from niche self-management to ecosystem-wide enabler, reducing global chronic care burdens—reinforcing its mission to rebuild care for billions through effective, patient-centered AI.[1][3]
Aide Health has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2022 | $1.0M Seed | American Express Ventures, B Capital Group, Blockchain Capital, Cedar Capital Group, Chemistry VC, Citi Ventures, Coinbase Ventures, Hambro Perks, Rajan Anandan, Tapas Capital, Pierre Lavaux, Scott Belsky, Trevor Wright |